EUVIMEDEUVIMED entdecken
Crossref

Opportunity for Improved Menopausal Hormone Therapy Prescribing

Deborah Bartz, Ananya Tadikonda, JoAnn E Manson

JAMA · 21.04.2026 · 335 (15) · 1297

DOI: 10.1001/jama.2026.1891 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 21.04.2026. Verfasst von Deborah Bartz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This Perspective discusses the implications of the recent US Food and Drug Administration (FDA) label change on menopausal hormone therapy for clinicians to better integrate hormone therapy options and personalized, shared decision-making to improve care for midlife women.

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Connors Center for Women's Health Research, Brigham and Women's Hospital, Boston, Massachusetts.
  • Harvard Medical School, Boston, Massachusetts.
  • Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Zitieren

APA

Bartz, D., Tadikonda, A., & Manson, J. E. (2026). Opportunity for Improved Menopausal Hormone Therapy Prescribing. JAMA, 335(15), 1297. https://doi.org/10.1001/jama.2026.1891

Vancouver

Bartz D, Tadikonda A, Manson JE. Opportunity for Improved Menopausal Hormone Therapy Prescribing. JAMA. 2026;335(15):1297. doi:10.1001/jama.2026.1891

BibTeX
@article{Bartz2026,
  author = {Bartz, Deborah and Tadikonda, Ananya and Manson, JoAnn E},
  title = {Opportunity for Improved Menopausal Hormone Therapy Prescribing},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {15},
  pages = {1297},
  doi = {10.1001/jama.2026.1891}
}
Kostenlos starten →